Comparative Pharmacology
Head-to-head clinical analysis: MIRALUMA versus QUADRAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRALUMA versus QUADRAMET.
MIRALUMA vs QUADRAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MIRALUMA (garadacimab) is a monoclonal antibody that binds to activated factor XII (FXIIa) and inhibits its activity, thereby blocking the contact activation pathway of the coagulation cascade. This prevents the generation of bradykinin, reducing vascular permeability and swelling in hereditary angioedema (HAE).
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
MIRALUMA (mirvetuximab soravtansine) is administered intravenously at 6 mg/kg adjusted ideal body weight (AIBW) once every 3 weeks until disease progression or unacceptable toxicity.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
None Documented
None Documented
20 hours; prolonged to 30-40 hours in renal impairment requiring dose adjustment
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
90% renal as unchanged drug; 10% biliary/fecal
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical